Prof Shankar Siva leads the Stereotactic Ablative Body Radiotherapy (SABR) program at the Peter Mac and is internationally recognised for his work in high technology radiotherapy delivery. He completed his PhD focusing on translational investigations in precision high-dose lung radiotherapy and published the first original research from Australia on the use of the SABR technique.

Shankar leads multiple clinical trials in the treatment of cancer, including investigator-initiated clinical trials led by TROG. His international commitments include positions on the Board of Directors of the Radiosurgery Society (RSS), the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) committee, American Society of Radiation Oncology (ASTRO) Science Council, and Course Director of European Society for Radiotherapy (ESTRO) SBRT Asia. He has research interests in high-tech radiotherapy delivery, SABR and radiation immunology.